At a glance
What is it—and why does it matter?
The labeled use indicates scalp hair regrowth for a product whose active ingredients include sr-Rainbow Trout Oligopeptide-1 components. The labeled directions specify topical application (face and neck) with a measured pump amount and frequency.
Sources for this introduction: [1] [2]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
The intervention described as a topical recombinant epidermal growth factor (REGF) serum is explicitly labeled as oligopeptide-1 in the study aim.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To compare the clinical efficacy, tolerability, and exploratory psychosocial perception outcomes of a topical recombinant epidermal growth factor (REGF), oligopeptide-1, serum with a human-derived growth factor (operationally labeled HDEGF) serum.”
A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception. · AIM
pubmed:42152512:22f234987457:22f234987457
Identity
Oligopeptide-1 is present in the formulation per the ingredient declaration.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“INGREDIENTSTremella Fuciformis Extract, Water (Aqua),Hydrolyzed Collagen, Glycerin, Sodium DNA,Oligopeptide-1, Oligopeptide-3, PentyleneGlycol, Hexylene Glycol, Hydroxyacetophenone”
dailymed-lead-435ecb5b · Untitled section
dailymed:435ecb5b-0d12-4da1-e063-6394a90a8be2:1a4bc35ee3cc:1a4bc35ee3cc - supports · Source-backed record
“INGREDIENIS :Tremella Fuciformis Extract, Water, Glycerin,Oligopeptide-1, Oligopeptide-3, PalmitoylTripeptide-5, Hexapeptide-9, Sodium DNA(PDRN),Macromolecular Hyaluronic Acid”
dailymed-lead-449634c8 · Untitled section
dailymed:449634c8-ff99-1387-e063-6294a90aef45:8bef8a07c1b1:8bef8a07c1b1
Identity
Human Oligopeptide-1 is present in the formulation as an inactive ingredient (i.e., included in the ingredient list but not designated as the active ingredient).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Inactive Ingredients: Water, Aloe Barbadensis Leaf Juice, Sodium Hyaluronate, Butylene Glycol, Arbutin, Betaine, Polyquaternium-51, Coceth-7(and)PPG-1-PEG-9 Lauryl Glycol Ether(and)PEG-40 Hydrogenated Castor Oil, Beta-Glucan, Morus Alba Bark Extract, Camellia Sinensis Leaf Extract, Caprylyl Glycol (and) Caprylhydroxamic Acid, Acetyl Hexapeptide-8, Arginine, Carbomer, Tocopheryl Acetate, Adenosine, Disodium EDTA, Dipotassium Glycyrrhizate, Human Oligopeptide-13, Human Oligopeptide-1, Fragrance.”
dailymed-lead-a3868721 · INACTIVE INGREDIENT
dailymed:a3868721-7531-4406-997a-eba4a4792aa0:7685b2d50f06:7685b2d50f06
How does it work?
Target, response, and disposition.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
What has been studied?
What the evidence says.
Study findings
The labeled use indicates scalp hair regrowth for a product whose active ingredients include sr-Rainbow Trout Oligopeptide-1 components.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To regrow hair on the scalp”
80592-203 · Use[s]
dailymed:aff6006a-6b46-fa2d-e053-2995a90a7fec:26c5d31c12cf:26c5d31c12cf
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
Administration
The labeled directions specify topical application (face and neck) with a measured pump amount and frequency.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Use: Dispense 1-2 pumps onto cleanfingertips. Gently apply to face and neck usingupward motions.Use morning and nightbefore moisturizer,”
dailymed-lead-449634c8 · Untitled section
dailymed:449634c8-ff99-1387-e063-6294a90aef45:8bef8a07c1b1:8bef8a07c1b1
Additional research & classification gaps
2 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (2)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source explicitly denies functional equivalence of sh-oligopeptide-1 to EGF at the level of biological function.
Research context only—not evidence of a treatment effect.
- Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?
Likewise, sh-oligopeptide-1 is not a functional EGF,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source states sh-oligopeptide-1 is marketed/treated as a cosmetic and is considered bioequivalent to epidermal growth factor (EGF).
Research context only—not evidence of a treatment effect.
- Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?
sh-oligopeptide-1 is a cosmetic that is considered to be the bioequivalent of the Epidermal Growth Factor (EGF).
Research status + gaps
What still needs better answers?
- No publishable claim yet for: contraindication, interaction, mechanism, regulatory, safety
- 72 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (42), assurance_score_below_0.72 (24), current_regulatory_source_required (18), extraction_ambiguity (59), high_risk_requires_regulatory_or_two_independent_sources (30), no_direct_support (66)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- dailymed-lead-435ecb5b ↗
dailymed · published 2025-11-11 · retrieved 2026-09-08T21:52:43Z
- dailymed-lead-449634c8 ↗
dailymed · published 2025-11-27 · retrieved 2026-09-08T21:52:38Z
- dailymed-lead-a3868721 ↗
dailymed · published 2019-04-11 · retrieved 2026-09-08T21:52:42Z
- 80592-203 ↗
dailymed · published 2020-10-05 · retrieved 2026-09-08T21:52:44Z
- Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud? ↗
pubmed · published 2023-12-01 · retrieved 2026-09-08T21:52:40Z
- A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception. ↗
pubmed · published 2026-05-01 · retrieved 2026-08-28T12:35:21Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T22:30:25Z
63939dd03a59e9f450191fba537ad52856ace41d23553031f1a3c742cc8877aa